Skip to main content

Table 2 Treatment for 843 HER2-positive BC patients

From: Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

TreatmentWithout trastuzumabWith trastuzumabp-value
Group 1
n(%)
Group 2
n(%)
Group 3
n(%)
Chemotherapy regimen
 EC-T203 (79.6)248 (84.4)238 (81.0)0.846
 TCb37 (14.5)35 (11.9)39 (13.3) 
 P8 (3.1)6 (2.0)10 (3.4) 
 Others7 (2.7)5 (1.7)7 (2.9) 
Radiotherapy
 No114 (44.7)124 (42.2)141 (48.0)0.369
 Yes141 (55.3)170 (57.8)153 (52.0) 
Endotherapy
 No142 (55.7)162 (55.1)160 (54.4)0.956
 Yes113 (44.3)132 (44.9)134 (45.6) 
Total255 (100.0)294 (100.0)294 (100.0) 
  1. Group 1 contained patients without trastuzuamb treatment, group 2 contained patients with trastuzuamb and low pre-NLR value, and group 3 contained patients with trastuzuamb and high pre-NLR value. EC-T, epirubicin and cyclophosphamide followed by the taxane; TCb, docetaxel and carboplatin; P, taxane; NLR, neutrophil/lymphocyte ratio